Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma
Completed
- Conditions
- Renal Cell Carcinoma
- Registration Number
- NCT01585974
- Lead Sponsor
- Bayer
- Brief Summary
This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 151
Inclusion Criteria
- To be diagnosed as metastatic renal cell carcinoma
- Previous cytokine therapy
- To sign informed consent form (ICF)
Exclusion Criteria
- Patients not willing to sign informed consent form or who withdraw their consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product After 2 years
- Secondary Outcome Measures
Name Time Method Incidence of treatment-emergent adverse events (TEAE) After 2 years Change of Tumor status Baseline and 2 years